Biotech company Polyrizon has successfully closed a private placement, raising $17 million in funds. The company specializes in developing intranasal hydrogels that act as a barrier against viruses and allergens. The funds will be used for general corporate purposes and working capital. Polyrizon's technology has the potential to serve as a "biological mask" through their Capture and Contain technology, delivered via nasal sprays.